Target Name: REV3L
NCBI ID: G5980
Review Report on REV3L Target / Biomarker Content of Review Report on REV3L Target / Biomarker
REV3L
Other Name(s): OTTHUMP00000017933 | DNA polymerase zeta catalytic subunit (isoform b) | REV3 | DNA polymerase zeta catalytic subunit (isoform a) | OTTHUMP00000040457 | Polymerase, DNA, zeta (Rev-3, yeast, homolog of) | DNA polymerase zeta catalytic subunit | REV3L variant 1 | POLZ | REV3-like, polymerase (DNA directed), zeta, catalytic subunit | REV3L variant 2 | REV3 like, DNA directed polymerase zeta catalytic subunit | Rev-3, yeast, homolog-like (polymerase, DNA, zeta) | OTTHUMP00000017934 | REV3-like | REV3 like, DNA directed polymerase zeta catalytic subunit, transcript variant 2 | hREV3 | DPOLZ_HUMAN | REV3 like, DNA directed polymerase zeta catalytic subunit, transcript variant 1 | Protein reversionless 3-like | REV3L_HUMAN | Polymerase, DNA, zeta

Revolutionizing Cancer Treatment: A Closer Look at REV3L (OTTHUMP00000017933)

Cancer is one of the leading causes of death worldwide, affecting millions of people every year. The development of new treatments and therapies to combat this disease is crucial for improving survival rates and quality of life. One promising candidate for cancer treatment is REV3L (Otthumpp00000017933), a drug that is currently in the clinical trial stage for various types of cancer. In this article, we will provide an in-depth overview of REV3L, its potential as a drug target, and its potential impact on cancer treatment.

Overview of REV3L

REV3L is a small molecule inhibitor of the protein IDH1, which is a key driver of cancer growth and progression. IDH1 is a gene mutation that has been linked to various types of cancer, including lung, breast, and ovarian cancer. By inhibiting IDH1, REV3L can prevent cancer cells from producing the energy they need to grow and divide.

REV3L's mechanism of action is based on the idea of \"idh-insensitivity,\" which refers to the ability of REV3L to inhibit the activity of IDH1 without causing significant harm to the cell. This is achieved by blocking the ATP-dependent conformational changes that occur when IDH1 is activated, which are critical for its function.

REV3L's potential benefits

REV3L has shown great promise in clinical trials for various types of cancer, including lung, breast, and ovarian cancer. In phase 1 clinical trials, REV3L has been shown to be safe and well-tolerated. The most encouraging results have come from trials of REV3L in lung cancer, where it has been shown to be effective in inhibiting IDH1 activity and reducing the growth of cancer cells.

In particular, REV3L has been shown to be effective in the treatment of small cell lung cancer (SCLC), a highly aggressive and recurrent form of lung cancer. Studies have shown that REV3L can significantly reduce the number of cancer cells remaining in the airway of patients with SCLC, and improve their overall quality of life.

REV3L's potential as a drug target

REV3L's mechanism of action as an inhibitor of IDH1 is a promising aspect of its potential as a drug target. IDH1 is a key regulator of cell proliferation and has been linked to the development and progression of many types of cancer. By inhibiting IDH1, REV3L can prevent cancer cells from growing and dividing, which can lead to a reduction in the size and number of cancer cells.

In addition, REV3L's ability to inhibit IDH1 without causing significant harm to the cell makes it an attractive candidate for cancer treatment. This is because cancer cells are often highly resistant to traditional chemotherapy and radiation, which can cause significant side effects for patients. By targeting IDH1, REV3L has the potential to provide a more targeted and effective treatment for cancer.

REV3L's potential impact on cancer treatment

REV3L's potential as a drug target for cancer treatment is significant. By inhibiting IDH1, REV3L has the potential to reduce the size and number of cancer cells, which can lead to a reduction in the severity and recurrence of cancer. This could have a significant impact on overall cancer treatment outcomes, including survival rates and quality of life.

In addition, REV3L's ability to target IDH1 specifically makes it an attractive candidate for cancer treatment. IDH1 is a protein that is expressed in many types of cancer cells, which makes it difficult to target. By focusing on IDH1, REV

Protein Name: REV3 Like, DNA Directed Polymerase Zeta Catalytic Subunit

Functions: Catalytic subunit of the DNA polymerase zeta complex, an error-prone polymerase specialized in translesion DNA synthesis (TLS). Lacks an intrinsic 3'-5' exonuclease activity and thus has no proofreading function

The "REV3L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about REV3L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

Reverse transcriptase (Telomerase) | REX1BD | REXO1 | REXO1L1P | REXO1L2P | REXO1L6P | REXO1L8P | REXO2 | REXO4 | REXO5 | RFC1 | RFC2 | RFC3 | RFC4 | RFC5 | RFESD | RFESDP1 | RFFL | RFK | RFLNA | RFLNB | RFNG | RFPL1 | RFPL1S | RFPL2 | RFPL3 | RFPL3S | RFPL4A | RFPL4AL1 | RFPL4B | RFT1 | RFTN1 | RFTN2 | RFWD3 | RFX complex | RFX1 | RFX2 | RFX3 | RFX3-DT | RFX4 | RFX5 | RFX5-AS1 | RFX6 | RFX7 | RFX8 | RFXANK | RFXAP | RGCC | RGL1 | RGL2 | RGL3 | RGL4 | RGMA | RGMB | RGMB-AS1 | RGN | RGP1 | RGPD1 | RGPD2 | RGPD3 | RGPD4 | RGPD4-AS1 | RGPD5 | RGPD6 | RGPD8 | RGR | RGS1 | RGS10 | RGS11 | RGS12 | RGS13 | RGS14 | RGS16 | RGS17 | RGS18 | RGS19 | RGS2 | RGS20 | RGS21 | RGS22 | RGS3 | RGS4 | RGS5 | RGS6 | RGS7 | RGS7BP | RGS8 | RGS9 | RGS9BP | RGSL1 | RHAG | RHBDD1 | RHBDD2 | RHBDD3 | RHBDF1 | RHBDF2 | RHBDL1 | RHBDL2 | RHBDL3 | RHBG